Kornimate/medical-research-clean huggingface dataset:
effectiveness of virtual reality gaming therapy versus ci therapy for upper extremity rehabilitation

Conditions: Stroke; Hemiparesis

Summary: the current proposal aims to conduct a multi-site randomized controlled trial comparing virtual-reality gaming delivery of constraint induced movement therapy (ci therapy) with (1) traditional clinic-based ci therapy of equal total active therapy duration and (2) a control group equating the dose of in-person therapy. individuals with chronic stroke will be randomized to one of four different interventions: (1) traditional clinic-based ci therapy (35 therapist/client contact hours), (2) therapist-as-consultant virtual reality ci therapy (5 therapist/client contact hours in the clinic and 15 hours of independent game play at home), (3) therapist-as-consultant virtual reality ci therapy with additional therapist contact via telerehabilitation (5 therapist/client contact hours in the clinic, 2.6 therapist contact hours via teleconference, and 15 hours of independent game play in the home), and (4) 5 hours of standard occupational therapy (ot) / physical therapy (pt). after 6-month follow-up, individuals assigned to standard ot/pt will cross over to a modified gaming therapy condition (a stand-alone application of the rehabilitation game without additional therapist contact).

detailed study description published in bmc neurology (2017).

Eligibility criteria:
inclusion criteria: * males, females, or any gender identity 18 years of age or older * experienced a stroke resulting in mild-to-moderate hemiparesis at least six months prior to enrollment (suggested range of motion (rom) criteria includes: 45° shoulder abduction and flexion, 20° elbow extension, 20° wrist extension, and 10° extension of thumb and finger) * have preserved ability to comprehend and participate in basic elements of the therapy exclusion criteria: * concurrent participation in other experimental trials for motor dysfunction treatment * receiving botox therapy currently or in the past 3 months * have medical conditions that would place volunteers at higher risk of adverse events (e.g., renal disease, frailty, pregnancy, dementia, severe pain, end-stage/degenerative diseases) * have received intensive upper-extremity rehabilitation in the chronic phase post-stroke

Keywords: constraint-induced movement therapy gaming virtual reality upper extremity ci therapy rehabilitation stroke hemiparesis therapy self-management in-home remote telerehabilitation
phase ii study of qls32015 combination therapy in the treatment of multiple myeloma

Conditions: Relapsed or Refractory Multiple Myeloma

Summary: the purpose of the study is to compare the efficacy of qls32105 (sc) in combination with pomalidomide, and qls32105 (sc) in combination with ql2109 or daratumumab, and qls32105 (sc) in combination with ql2109 or daratumumab and pomalidomide, and qls32105(sc) in combination with bortezomib and lenalidomide.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple myeloma confirmed according to the 2016 international myeloma working group (imwg) diagnostic criteria; * prior therapy: relapsed, progressed, or intolerant to ≥1 prior line of anti-multiple myeloma therapy; * measurable disease at screening, defined by at least one of the following: * serum m-protein ≥1.0 g/dl (10 g/l); * urine m-protein ≥200 mg/24 hours; * serum immunoglobulin free light chain ≥10 mg/dl (100 mg/l) with an abnormal serum immunoglobulin κ/λ free light chain ratio. exclusion criteria: * history of grade 3 or higher cytokine release syndrome (crs) associated with any t-cell redirecting therapy (e.g., cd3-redirecting technologies or car-t cell therapy); * prior anti-myeloma therapies within the specified timeframes before enrollment: * previous treatment with gprc5d-targeted therapy; * genetically modified adoptive cell therapy (e.g., chimeric antigen receptor t-cell \[car-t\], natural killer \[nk\] cell therapy) within 3 months; * targeted therapy, investigational drugs, or invasive investigational medical devices within 21 days or 5 half-lives (whichever is longer); * monoclonal antibodies or bispecific antibody therapy for multiple myeloma within 21 days or 5 half-lives (whichever is longer); * cytotoxic therapy within 21 days; * proteasome inhibitor therapy within 14 days; * immunomodulatory drug therapy within 7 days; * radiotherapy within 14 days (except low-dose palliative radiation \[10-30 gy\]); * prior intolerance to pomalidomide (applies to treatment cohorts containing pomalidomide); * prior intolerance to bortezomib (applies to treatment cohorts containing bortezomid); * prior intolerance to lenalidomide (applies to treatment cohorts containing lenalidomide); * prior intolerance to daratumumab (applies to treatment cohorts containing daratumumab).
treatment of post-traumatic brain injury (post-tbi) fatigue with light therapy

Conditions: Traumatic Brain Injury; Fatigue

Summary: this study aims to evaluate the efficacy of 4 weeks of daily light exposure in reducing post-traumatic brain injury (tbi) fatigue immediately post-treatment and at a one-month follow up. the investigators hypothesize that individuals receiving 4 weeks of bright white light treatment will report significant reductions in fatigue compared to individuals receiving dim red light treatment for the same duration of time, and that these treatment effects will be maintained one month after treatment completion.

to determine the efficacy of bright white light exposure compared to dim red light exposure in reducing post-tbi fatigue, an 8-week, randomized parallel-group clinical trial will be performed. outcome assessment will be blinded. participants will complete a baseline battery (t1) including 72 hours of actigraphy. participants will then be randomized to either the bright white light (bwl) or the dim red light (drl) group. after 4 weeks of daily, 30-minute light treatments, the baseline battery will be re-administered (t2) along with 3 more days of actigraphy. a follow-up assessment involving the same measures will be administered 1 month-post cessation of light therapy (t3). participant treatment allocations will be masked for research team members conducting outcome measures. secondary outcome measures will be administered to explore the effects of light therapy on mood, daytime sleepiness, sleep quality, circadian rhythms, anxiety, cognition and life satisfaction.

Eligibility criteria:
inclusion criteria: * documented tbi of any severity * at least 6 months post injury * presence of clinically significant fatigue, operationalized as a score of 22 or more on the multidimensional assessment of fatigue * age 18 or older * english speaking exclusion criteria: * neurological disease other than tbi * pregnancy (because of pregnancy fatigue) * medical illness causing fatigue, such as anemia, hypothyroidism, hiv, renal failure, cirrhosis or cancer treatment in the past year * current major depressive episode or substance abuse * diagnosed sleep disorder or high risk for sleep apnea * history of bipolar disorder or manic or hypomanic episodes * current chronic, severe headaches * sensitivity to bright light * history of retinal damage or disease

Keywords: traumatic brain injury tbi fatigue post-tbi fatigue ptbif depressed mood excessive daytime sleepiness circadian rhythm anxiety cognitive dysfunction intervention treatment
decitabine and plerixafor in elderly acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: the hypothesis of this proposal is that combining plerixafor, an inhibitor of stromal cell derived factor - 1α (sdf-1α), with decitabine, a dna methyltransferase inhibitor, as induction and postremission therapy for older patients with acute myeloid leukemia (aml) will improve treatment outcomes via mobilization of leukemia stem cells and alteration of the pharmacodynamics of decitabine. the protocol will establish the safety and feasibility of combining two different doses of plerixafor with a fixed dose and schedule of decitabine.


Eligibility criteria:
inclusion criteria: * unequivocal pathologic diagnosis of aml (≥ 20% blasts in the bone marrow based on who criteria) excluding: i) acute promyelocytic leukemia t(15;17)(q22;q12); pml-rara; ii)acute myeloid leukemia with t(8;21)(q22;q22); runx1-runxt1; iii) acute myeloid leukemia with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); cbfb-myh11. * aml patients with an antecedent hematologic disorder or myelodysplastic syndrome (mds)are eligible for treatment on this trial provided that they have not received prior treatment with decitabine or prior cytotoxic treatment for aml. * aml patients with therapy-related myeloid neoplasms (t-mn) are eligible if they have not received chemotherapy (not including hormonal therapy) for their primary malignancy or disorder for \>6 months. * age ≥ 60 years. * ability to understand and willingness to sign a written informed consent document. exclusion criteria: * prior treatment with decitabine * prior treatment with plerixafor * ongoing treatment for another malignancy. * patients with good-risk molecular or cytogenetics features * patient has a medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational drug treatment. * patient has a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies. * patient has an inability or unwillingness, in the opinion of the investigator, to comply with the protocol requirements.

Keywords: leukemia
evaluation of spa medicine on the example of comprehensive therapy in the spa resort przerzeczyn zdroj

Conditions: Osteoarthritis; Degenerative Disc Disease

Summary: observation conducted during the 21 days of treatment in the health resort of przerzeczyn zdroj. in a treatment of applied therapy: redon-sulfide baths, partial mud baths, kinesitherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. study group with joint or back pain due to osteoarthritis or degenerative disc disease. the control group was selected by the spa workers, healthy individuals, nonsmokers, who did not drink alcohol. it was recommended to retain the previous lifestyle and use of resort's facilities was prohibited. in both of these groups, appropriate pre- and post-treatment studies were performed.

the observation was conducted during 21 days of medicinal stays in the health resort of przerzeczyn zdroj. the treatment included a comprehensive therapy: redon-sulfide baths, partial mud baths, kinesitherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. the study group consisted of patients with joint or back pain due to osteoarthritis or degenerative disc disease.participating in therapy. on the day of admission to the spa the patients were subjected to subjective and objective examination. laboratory tests (lipids profile, crp, smear blood morphology, tas- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. in addition, before and after treatment, standard scales were used to assess pain intensity vas scale and anxiety and depression levels - hads scale. the control group was selected by the spa workers. on the day of admission to the spa the patients were subjected to subjective and objective examination. laboratory tests (lipids profile, crp, smear blood morphology, tas- total antioxidative potential, the concentration of endorphins and serotonin) were performed before treatment on day 5 and after 18 days. in addition, before and after treatment, standard scales were used to assess pain intensity: vas scale and anxiety and depression levels - hads scale.

Eligibility criteria:
inclusion criteria: * the presence of degenerative disc disease and/or osteoarthritis ; * age range 30-69 years; * the written consent to participate in research; * no impediment to comprehensive treatment at the spa. exclusion criteria: * the lack of consent to participate in research; * the age under 30 and over 70 years; * the presence of diseases constituting a contraindication to therapy (compatible with the standard list of indications and contraindications to spa therapy);
preventative intervention for cholera for 7 days

Conditions: Cholera; Water-Related Diseases; Diarrhea Infectious

Summary: the first objective of our study is to develop a theory-driven evidence-based targeted water, sanitation, and hygiene (wash) intervention for household members of diarrhea patients in south kivu, democratic republic of the congo (drc) through formative research and community engagement. the second objective is to conduct a randomized controlled trial of 2,320 household members of 580 severe diarrhea patients to evaluate the effectiveness of the developed targeted wash intervention in terms of: 1. reducing diarrheal diseases household members of cholera and severe diarrhea patients; and 2. increasing wash behaviors.

this study develops and evaluates a targeted water, sanitation, and hygiene (wash) intervention to reduce cholera and severe diarrhea among the household members of diarrhea patients in south kivu, democratic republic of the congo (drc) through formative research and a randomized controlled trial. this study will also investigate cholera and severe diarrhea transmission dynamics among diarrhea patient households using genomics and a risk factor analysis. the study will be divided into two phases: (1) the formative research and intervention development phase; and (2) the intervention implementation and evaluation phase. in the two arm randomized controlled trial of diarrhea patient households, we compare the standard message given in drc to diarrhea patients to the picha7 mhealth program. the standard message arm is the standard recommendation given in drc to diarrhea patients at discharge on the use of oral rehydration solution (ors) for dehydration, and the importance of handwashing with soap and water treatment for disease prevention. the picha7 mhealth program arm will first be delivered during a health facility visit by a health promoter bedside to a diarrhea patient (adults and child) and their accompanying household members during the time of illness followed by two home visits during the 7-day high risk period for diarrheal disease transmission. the health promoter delivers a pictorial wash module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. a diarrhea prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. after health facility delivery of the program, patient households receive weekly voice and text messages from the picha7 mhealth program over 12 months on the recommended wash behaviors.

Eligibility criteria:
inclusion criteria: * diarrhea patients presenting with three or more loose stools over a 24h period * having no running water inside of their home * plan to reside in bukavu for the next 12 months * have a child \<5 years in their household * have a working mobile phone in the household exclusion criteria: * no one will be excluded because of age, sex, religion, or sexual preference * presenting at the health facility with a fever (covid-19 prevention)
pirfenidone and its role in burn wound healing

Conditions: Second-degree Burn

Summary: burn patients which skin has been lost a rapid growth of the skin is a foremost in their treatment. due to the injury, burn patients undergo a systemic inflammation that helps the skin heal faster. however, several studies have shown that this inflammation increases the levels of several inflammatory molecules that impairs skin growing, which further delays the recovery of burn patients. as such, by inhibiting these inflammatory molecules with the administration of a medication called pirfenidone burn patients might present faster rates of skin growth and recovery. thus, patients suffering from a burn injury will be recruited at the emergency department of the hospital university in monterrey mexico. afterward, patients will be randomized to either receive pirfenidone 600 mg orally once per day or usual care consisting of covering the wound with hydrocolloid dressings. to assess the amount of newly growth skin investigators will take a small piece of the skin to further evaluate it through a microscope.


Eligibility criteria:
inclusion criteria: * patients with second-degree burns from any etiology with less than 24 hours of evolution. exclusion criteria: * patients \<18 years old * patients allergic to pirfenidone * pregnant patients * patients with renal or hepatic failure * patients who are not able to take the medication orally * conditions or drugs that alter wound healing (i.e. any kind of diabetes, lupus, having a history of using steroids, rheumatoid arthritis)

Keywords: burns partial-thickness burn wounds re-epithelization second-degree wound pirfenidone wound healing
pancreatic insufficiency secondary to tobacco exposure

Conditions: Pancreatic Insufficiency

Summary: pancreatic insufficiency is a condition in which there is a decrease in the production and release of enzymes made in the pancreas, which causes nutrient malabsorption. there are many chronic diseases that can lead to pancreatic insufficiency. in the early stages of this disease, a patient may not experience any symptoms, and the prevalence of pancreatic insufficiency may be underestimated. smoking has long been recognized as a cause of disease in many organs in the body. cigarette smoke causes inflammation and damages tissue, including the pancreas. studies have shown that smoking is an independent risk factor for pancreatic cancer and chronic pancreatitis. it has also been shown that the more a person smokes, the worse his disease will be. additionally, there are studies that show that smokers have nutritional deficiencies. there are observational and retrospective studies that suggest that pancreatic insufficiency may also be caused by smoking. however, this has not been established, and the relationship has not been examined in a controlled manner. this study examines the relationship between smoking and pancreatic insufficiency in patients who do not have other pancreatic diseases.


Eligibility criteria:
inclusion criteria: 1. male or female at least 30 years of age 2. able to read, understand, and sign informed consent 3. patients with a negligible smoking history (defined as no smoking for the past 7 years, and a total smoking history ≤ 5 pack-years) or patients with at least a 20 pack-year smoking history exclusion criteria: 1. patients with a prior diagnosis of pancreatic insufficiency 2. patients who have a current or remote history of acute or chronic pancreatitis or any other primary pancreatic disease or malignancy 3. patients who have had pancreatic surgery 4. patients with a diagnosis of small bowel malabsorption or celiac disease 5. patients with any other significant systemic disease that is deemed by the investigator as possibly interfering with the conduct or interpretation of the study

Keywords: pancreatic insufficiency pancreatic elastase fecal elastase smoking tobacco
cope with copd trial

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the overall objective of this study is to evaluate a collaborative self-management intervention in patients with moderate to severe copd in a primary care population. to achieve this objective the investigators developed a diagnostic and treatment pathway for the management of copd in primary care that is based on national guidelines and focused on patient self-management. .


Eligibility criteria:
inclusion criteria: * current or ex-smokers * 40 years of age or over * minimum 10 pack year smoking history * post-bronchodilator fev1 of 70% or less (4 puffs of salbutamol) and forced expiratory volume at 1sec to forced vital capacity (fev1/fvc) ratio 70% or less * a history of two exacerbations (involving treatment and/or visit to a health care practitioner) in the past 3 years or 1 exacerbation in the past year * provides informed consent exclusion criteria: * copd exacerbation in the past 4 weeks * diagnosis of asthma prior to the age of 40 years * co-existing illness that could interfere with study results (ie. congestive heart failure with exacerbation of symptoms) * scheduled for copd rehabilitation * a terminal illness
study of sc-fos for pouchitis prevention

Conditions: Pouchitis

Summary: the main objective is to compare prebiotic therapy with placebo for the prevention of pouchitis after closure of diverting ileostomy in patients with an ileal pouch anal anastomosis. this study will also characterize the effects of prebiotics on the fecal microbiota and fecal microbial metabolites and correlate these effects with the primary outcome of development of pouchitis.


Eligibility criteria:
inclusion criteria: 1. age 18-65 years. 2. history of ulcerative colitis 3. ileostomy closure after ipaa 4. ability to give appropriate consent exclusion criteria: 1. crohn's disease. 2. perianal disease (including abscess, fissure, or stricture) 3. pregnancy 4. lactation 5. concurrent treatment for ibd or pouchitis
strength training for men living with obesity

Conditions: Obesity

Summary: emerging evidence suggests that alternative obesity management strategies need to address barriers to engaging with regular physical activity to adopt healthier lifestyles. it is hypothesized that more men living with obesity who are exposed to an online home-based circuit strength training for 12 weeks will be more physically active, 34 weeks after the intervention compared with people who are not exposed to the program.

sixty men (age ≥ 18 years; body fat % ≥ 25) were randomly assigned to the intervention group (n=30) or the control condition (n=30) for 12 weeks. the intervention group did the online delivered circuit training, three sessions in a week. adherence to the weekly physical activity guidelines was evaluated 46 weeks after being enrolled in the program using a heart rate tracker and an exercise log. most variables (anthropometrics, body composition, resting heart rate, blood pressure, lipids profile, glucose) were measured at baseline and after 12, 24, and 46 weeks. aerobic fitness and comfort with technology were measured at baseline. perceived benefits/barriers of participation in exercise were captured at baseline and 12 weeks. more participants in the intervention group adhered to the physical activity guidelines compared to the control group at 46 weeks (intervention 36.8% vs control 5.3%; p=0.021). however, the intervention group did not improve their health outcomes after 12, 24, and 46 weeks. fewer barriers were reported after 12-week for the intervention group (p=0.02).

Eligibility criteria:
inclusion criteria: * men * body fat% of 25% or more * not reaching physical activity guidelines (150 min of moderate to vigorous intensity of aerobic exercises + two sessions of resistance training) * being able to do weight training exclusion criteria: - taking medications that can cause to change in heart rate

Keywords: physical activity men strength training